BCDA Earnings Prediction
The chart below shows how BCDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BCDA sees a +6.12% change in stock price 10 days leading up to the earnings, and a -0.34% change 10 days following the report. On the earnings day itself, the stock moves by +0.40%. This data can give you a slight idea of what to expect for the next quarter's release.
BCDA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
-100.00%
-100.00%
Gross Margin
--
--
--
Operating Margin
-9793.10%
1245.71%
-82.18%
Net Margin
-9741.38%
1251.07%
-82.25%
EPS
-0.61
-408.33%
-30.68%
No Data Available
BCDA Earnings Analysis
BioCardia, Inc. Common Stock Corporation (BCDA.O) Earnings Conference Call
Positive
Expense Reduction Quarter-over-Quarter: Total expenses decreased 41% quarter-over-quarter to $1.8 million in Q3 2024, compared to $3.0 million in Q3 2023.
R&D Expense Reduction: Research and development expenses decreased to $931,000 during the third quarter of 2024, compared to $1.9 million for the third quarter of 2023, primarily due to the completion of enrollment in the Cardiac AMP Heart Failure I trial.
Net Loss Reduction: Net loss decreased to $1.7 million for the third quarter of 2024, down from $2.6 million in the prior year's third quarter, primarily due to reductions in R&D and SG&A expenses.
Cash Flow Improvement: Cash flows for the nine months ended September 2024 were $5.5 million, which is $2.6 million less than the same nine-month period in 2023, indicating improved cash management.
R&D Expense Increase Expected: We expect R&D expenses to increase modestly as the Cardiac AMP Heart Failure II trial ramps up beginning in the fourth quarter of 2024.
Negative
Expense Reduction Quarter-over-Quarter: Total expenses decreased 41% quarter-over-quarter to $1.8 million in Q3 2024, compared to $3.0 million in Q3 2023.
R&D Expense Reduction: Research and development expenses decreased to $931,000 during the third quarter of 2024, compared to $1.9 million for the third quarter of 2023, primarily due to the completion of enrollment in the Cardiac AMP Heart Failure I trial coupled with related reductions in clinical and supporting functional expenses.
Net Loss Reduction: Net loss decreased to $1.7 million for the third quarter of 2024, down from $2.6 million in the prior year's third quarter, primarily due to those reductions in R&D and SG&A expense.
Operational Cash Flow Analysis: Net cash used in operations for the third quarter of 2024 totaled $2.6 million, compared to $2.4 million in the third quarter of 2023, indicating an increase due to our settling of trade payables and accrued liabilities following the closing of the $7.2 million public offering in September.
Cash Burn Management: We expect our cash burn will increase moderately over the coming year, continuing our track record of operating efficiently and carefully managing the use of capital.
BCDA FAQs
How does BCDA typically perform around its earnings report dates?
Is BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BCDA Earning Call Sentiment
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BCDA.O
-0.39%Positive
The earnings call presents a mixed but generally positive outlook. The FDA approval for the Morph DNA platform and Medicare coverage for CardiAMP are significant positives, indicating potential growth. Decreased expenses and a public offering improve financial stability. However, risks like competitive pressures and economic factors remain. The Q&A section shows management's proactive approach to partnerships but lacks some clarity on specifics. Overall, the positives slightly outweigh the negatives, suggesting a likely positive stock price movement.